Page last updated: 2024-09-02

tadalafil and cyclic gmp

tadalafil has been researched along with cyclic gmp in 87 studies

Compound Research Comparison

Studies (tadalafil)	Trials (tadalafil)	Recent Studies (post-2010) (tadalafil)	Studies (cyclic gmp)	Trials (cyclic gmp)	Recent Studies (post-2010) (cyclic gmp)
1,742	392	1,089	22,346	333	4,062

Protein Interaction Comparison

Protein	Taxonomy	cyclic gmp (IC50)
Phosphodiesterase	Bos taurus (cattle)	0.1
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	2.4
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)	2.4

Research

Studies (87)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (28.74)	29.6817
2010's	49 (56.32)	24.3611
2020's	13 (14.94)	2.80

Authors

Authors	Studies
McKenna, KE; Rosen, RC	1
Coste, H; Daugan, A; Grondin, P; Hyafil, F; Kirilovsky, J; Labaudinière, R; Le Monnier de Gouville, AC; Ruault, C	1
Coste, H; Daugan, A; Grondin, P; Hyafil, F; Kirilovsky, J; Labaudinière, R; Le Monnier de Gouville, AC; Linget, JM; Ruault, C	1
Beasley, A; Bessay, EP; Blount, MA; Corbin, JD; Francis, SH; Sekhar, KR; Zoraghi, R	1
Kloner, RA	1
Aufiero, K; Belardi, D; Champion, HC; Dostmann, WR; Isoda, T; Kass, DA; Mergia, E; Mongillo, M; Montrose, DC; Moslehi, J; Smith, CJ; Takimoto, E; Zaccolo, M	1
Antunes, E; Baracat, JS; Claudino, MA; De Nucci, G; Priviero, FB; Teixeira, CE; Webb, RC	1
Seftel, AD	1
Gonzalez-Cadavid, N; Magee, T; Nolazco, G; Qian, A; Rajfer, J; Vernet, D	1
Chopp, M; Cui, Y; LaPointe, MC; Silver, B; Zhang, L; Zhang, RL; Zhang, Z	1
Beasley, A; Bessay, EP; Blount, MA; Corbin, JD; Francis, SH; Grimes, KA; Zoraghi, R	2
Gustafsson, LE; Hallén, K; Wiklund, NP	1
Abdel Aziz, AT; Abdel Aziz, MT; Atta, H; El-Shehaby, AM; Hassouna, AA; Marzouk, SA; Mostafa, T; Obaia, EM; Rashed, L; Sabry, D	1
Biagioli, A; Caretta, N; Caretti, L; Foresta, C; Galan, A; Poletti, A; Zuccarello, D	1
Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Tilki, D; Uckert, S	1
Beasley, A; Bessay, EP; Blount, MA; Corbin, JD; Francis, SH; Zoraghi, R	1
Corbin, JD; Francis, SH; Zoraghi, R	2
Atta, H; Aziz, AT; Aziz, MT; El-Shehaby, AM; Hassouna, AA; Marzouk, SA; Mostafa, T; Obaia, EM; Rashed, L; Sabry, D	1
Imaoka, T; Uenaka, K; Yamaguchi, T	1
Cho, HJ; Kim, BK; Kim, CJ; Kim, KH; Kim, SC; Kim, SE; Kim, SH; Kim, TS; Ko, IG; Shin, DH; Shin, MC; Shin, MS; Sung, YH	1
Baumgartner, WA; Champion, HC; Shah, AS; Weiss, ES; Williams, JA	1
Argiolas, A; Boi, A; Melis, MR; Sanna, F; Succu, S	1
Akif Bayar, M; Erdem, Y; Gokcek, C; Karatay, M; Kilic, C; Koktekir, E	1
Beardsworth, A; Fujita, K; Kato, M; Nakazawa, T; Sawamura, F	1
Ma, M; Teng, Y; Xu, W	1
Bassi, P; Bonanni, G; Cella, G; De Bon, E; Saggiorato, G	1
Das, A; Durrant, D; Koka, S; Kukreja, RC; Xi, L; Zhu, SG	1
Berger, P; Pernkopf, D; Plas, E; Sampson, N; Untergasser, G; Zenzmaier, C	1
Ahmed, RP; Ashraf, M; Haider, HKh; Jiang, S; Lee, YJ; Ryon, M	1
Abadi, AH; Ahmed, NS; Gary, BD; Laufer, S; Piazza, GA; Tinsley, HN	1
Antunes, E; Arruda, AM; Barillas, S; Capel, RO; Cogo, JC; De Nucci, G; de Oliveira, MA; Mónica, FZ; Muscará, MN; Nahoum, C; Pissinatti, A; Pissinatti, L; Porto, M; Schenka, AA; Teixeira, SA	1
Beghyn, TB; Bourin, A; Charton, J; Cos, P; Deprez, B; Laconde, G; Leroux, F; Maes, L	1
Castro, RR; Cunha, FQ; Girão, VC; Leite, AC; Leite, AK; Rocha, FA; Silva, FS	1
Corbin, JD; Francis, SH	1
Bian, W; Fu, Q; Zhang, MY	1
Klinger, JR	1
Kotb, K; Mostafa, T; Rashed, L; Taymour, M	1
Kass, DA	1
Cahill, KB; Carleton, KL; Cote, RH; Quade, JH	1
Gaudó Navarro, J; Sueiro Bendito, A	1
Andersson, KE; Gratzke, C; Herlemann, A; Sievert, KD	1
Angulo, J; Chen, M; Cuevas, P; Fernández, A; González-Corrochano, R; La Fuente, J; Sáenz de Tejada, I	1
Guo, H; Hong, B; Jin, Z; Li, L; Zhang, J; Zhang, S; Zhi, H	1
Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Nesi, G; Santi, R; Sebastianelli, A; Serni, S; Vignozzi, L	1
Abadi, AH; Chang, WC; Chen, X; Clapper, ML; Gary, BD; Grizzle, WE; Gurpinar, E; Keeton, AB; Li, N; Li, Y; Moyer, MP; Piazza, GA; Tinsley, HN; Xi, Y; Zhu, B	1
Baseskioglu, AB; Erol, K; Ozatik, FY; Ozatik, O; Sirmagul, B; Yigitaslan, S	1
Barbaro, NR; Calhoun, D; Coelho, OR; de Faria, AP; Ferreira-Melo, SE; Fontana, V; Matos-Souza, JR; Modolo, R; Moreno, H; Santos, RC; Yugar-Toledo, JC	1
Derderian, SC; Etemadi, M; Fineman, JR; Gong, W; Iqbal, C; Johengen, M; Miniati, D; Oishi, P; Schecter, SC; Shue, EH	1
Angulo, J; Cardoso, J; Cuevas, P; Fernández, A; La Fuente, JM; Martínez-Salamanca, JI; Wright, HM	1
Abdel Aziz, MT; Ahmed, HH; Atta, HM; Fouad, H; Rezq, AM; Sabry, D; Yehia, HM; Zaahkouk, AM	1
Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Lasker, GF; Pankey, EA; Sikka, SC	1
Chen, HX; Gong, Y; Hong, D; Hu, XH; Ji, X; Shi, W; Wang, HB; Wang, JR; Wu, XM; Xu, CY	1
Aronsen, L; Lysaa, R; Orvoll, E; Ravna, AW; Sager, G	1
Al-Amin, MM; Alam, MA; Alam, T; Didar, RR; Hasan, AT; Hasan, SM; Hossain, I; Rahman, MM	1
Bentley, S; Magee, AG; Makhecha, S	1
Bednorz, M; Ghofrani, HA; Grimminger, F; Parajuli, N; Pichl, A; Schermuly, RT; Seeger, W; Seimetz, M; Weissmann, N	1
Otari, KV; Upasani, CD	1
Ben-Jonathan, N; Fox, SR; Mierzwa, ML; Tuttle, TR; Wells, SI	1
Baines, CP; Burnett, JC; Chakir, K; Cruz Rivera, N; Domeier, TL; Dozier, DG; Emter, CA; Ferguson, BS; Gutiérrez-Aguilar, M; Heublein, DM; Hiemstra, JA; Ivey, JR; Krenz, M; Lee, DI; Marshall, KD; McDonald, KS; Minervini, G; Scherf, C; Zgoda, PJ	1
Burgoyne, JR; Eaton, P; Grover, S; Kass, D; Prysyazhna, O; Scotcher, J	1
Bajraktari, G; Bugert, P; Burhenne, J; Haefeli, WE; Weiss, J	1
Hosoda, H; Ikeda, T; Ikemura, K; Kamimoto, Y; Katayama, K; Kondo, E; Kubo, M; Ma, N; Maki, S; Miyoshi, T; Nii, M; Okuda, M; Osato, K; Tanaka, H; Tanaka, K; Umekawa, T; Yoshida, T; Yoshikawa, K	1
Thenappan, T; Weir, EK	1
Cardarelli, S; Cichero, E; Di Rocco, G; Fossa, P; Franchini, S; Giorgi, M; Guerrini, R; Martinelli, I; Pacifico, S; Ponterini, G; Sola, M	1
Ceci, R; Di Luigi, L; Duranti, G; Sabatini, S; Sgrò, P	1
Frankenreiter, S; Friebe, A; Groneberg, D; Krieg, T; Kuret, A; Lukowski, R; Ruth, P	1
Domiati, S; El Mallah, A; Mehanna, MM; Nakkash Chmaisse, H	1
Jia, H; Levine, MA; Qin, L; Tower, RJ; Wang, L	1
Batten, A; Buys, ES; Dordea, AC; Fei, F; Gregory-Ksander, M; Mertz, J; Pasquale, LR; Sappington, RM; Schleifer, G; Wareham, LK; Yao, V	1
De Nucci, G; Lescano, CH; Pires de Oliveira, I	1
Abdelmonsif, DA; Boraie, N; Elbardisy, B; Galal, S	1
Ding, S; Huang, X; Liu, L; Song, G; Wang, D; Xu, H	1
Magdy, Y; Sedky, AA	1
Alexandre, EC; Antunes, E; Bertollotto, GM; Calmasini, FB; de Oliveira, MG; Jacintho, FF; Justo, AFO; Mónica, FZ	1
Abd Al Haleem, EN; Arafa, HMM; Ibrahim, FAM; Zaytoon, SAB	1
Amelinia, F; Belaran, M; Fanoudi, S; Mirzaei, H; Pourheidar, S; Tabrizian, K	1
Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Yar, MS; Zameer, S	1
Burnett, JC; Chen, HH; Hodge, DO; McKie, PM; Slusser, JP; Wan, SH	1
Adel, FW; Benike, SL; Burnett, JC; Chen, HH; Hubers, SA; Scott, C; Wan, SH	1
Antinozzi, C; Aversa, A; DI Luigi, L; Dimauro, I; Greco, EA; Sgrò, P	1
Skoularigis, J; Starling, RC; Triposkiadis, F; Xanthopoulos, A	1
Watanabe, H	1
Otari, KV; Patil, RJ; Upasani, CD	1
Antunes, E; de Gomes, ET; de Oliveira, MG; Leonardi, GR; Mónica, FZ; Passos, GR; Zapparoli, A	1
Angielski, S; Audzeyenka, I; Kulesza, T; Myślińska, D; Piwkowska, A; Rachubik, P; Rogacka, D; Szrejder, M	1

Reviews

12 review(s) available for tadalafil and cyclic gmp

Article	Year
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annual review of sex research, 2002, Volume: 13 Topics: Carbolines; Clinical Trials as Topic; Cyclic GMP; Erectile Dysfunction; Female; Humans; Imidazoles; Male; Muscle, Smooth; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents	2002
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation, 2004, Nov-09, Volume: 110, Issue:19 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Arteriosclerosis; Blood Pressure; Carbolines; Contraindications; Coronary Disease; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Endothelium, Vascular; Erectile Dysfunction; Heart Rate; Humans; Hypotension; Imidazoles; Isosorbide Dinitrate; Male; Molecular Structure; Myocardial Infarction; Nitric Oxide Donors; Nitroglycerin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents	2004
Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. Current pharmaceutical design, 2005, Volume: 11, Issue:31 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride	2005
[Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 131, Issue:6 Topics: Blood Pressure; Carbolines; Cyclic GMP; Erectile Dysfunction; Food-Drug Interactions; Humans; Male; Muscle Relaxation; Muscle, Smooth; Penis; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Randomized Controlled Trials as Topic; Tadalafil	2008
Tadalafil for the treatment of pulmonary arterial hypertension. Expert review of respiratory medicine, 2011, Volume: 5, Issue:3 Topics: Blood Pressure; Carbolines; Cyclic GMP; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Natriuretic Peptides; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Treatment Outcome; Vasodilator Agents	2011
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. Current heart failure reports, 2012, Volume: 9, Issue:3 Topics: Carbolines; Cardiomyopathy, Dilated; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Heart; Heart Failure; Humans; Hypertrophy; Myocardium; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Transforming Growth Factor beta; TRPC Cation Channels; Ventricular Remodeling	2012
[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. Archivos de bronconeumologia, 2011, Volume: 47 Suppl 7 Topics: Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Drug Interactions; Exercise Tolerance; Humans; Hypertension, Pulmonary; Molecular Structure; Phosphodiesterase 5 Inhibitors; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Second Messenger Systems; Tadalafil	2011
[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors]. Der Urologe. Ausg. A, 2013, Volume: 52, Issue:2 Topics: Carbolines; Controlled Clinical Trials as Topic; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Urodynamics; Vardenafil Dihydrochloride	2013
Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children. Expert opinion on drug safety, 2015, Volume: 14, Issue:5 Topics: Animals; Child; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil	2015
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease. Brain research bulletin, 2019, Volume: 153 Topics: Alzheimer Disease; Animals; Cognition; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Flavonoids; Humans; Neurons; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Purinones; Pyrimidines; Signal Transduction; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride	2019
Effects of tadalafil on skeletal muscle tissue: exploring interactions and novel mechanisms of action. Minerva endocrinology, 2023, Volume: 48, Issue:2 Topics: Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Hormones; Insulins; Muscle, Skeletal; Phosphodiesterase 5 Inhibitors; Tadalafil	2023
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart failure reviews, 2022, Volume: 27, Issue:6 Topics: Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Guanosine Monophosphate; Guanylate Cyclase; Heart Failure; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Retrospective Studies; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Vasodilator Agents	2022

Trials

6 trial(s) available for tadalafil and cyclic gmp

Article	Year
Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. Eye (London, England), 2008, Volume: 22, Issue:1 Topics: Adult; Blood Flow Velocity; Blotting, Western; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Ophthalmic Artery; Phosphodiesterase Inhibitors; Piperazines; Purines; Retina; Sildenafil Citrate; Statistics as Topic; Sulfones; Tadalafil; Time Factors	2008
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. The Prostate, 2013, Volume: 73, Issue:13 Topics: Aged; Aged, 80 and over; Carbolines; Cyclic GMP; Double-Blind Method; Humans; Imidazoles; Inflammation; Interleukin-8; Lower Urinary Tract Symptoms; Male; Middle Aged; Myofibroblasts; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Prostate; Prostatic Hyperplasia; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride	2013
Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. European journal of clinical pharmacology, 2014, Volume: 70, Issue:2 Topics: Aged; Blood Pressure; Carbolines; Cross-Over Studies; Cyclic GMP; Diastole; Drug Resistance; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Natriuretic Peptide, Brain; Nitrites; Phosphodiesterase 5 Inhibitors; Single-Blind Method; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left	2014
Acute tadalafil administration increases plasma fatty acids without changes in the inflammatory response in healthy men. Acta biochimica Polonica, 2017, Volume: 64, Issue:4 Topics: Adult; Blood Glucose; Cyclic GMP; Double-Blind Method; Fatty Acids; Glycerol; Humans; Inflammation; Interleukin-6; Interleukin-8; Male; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Tadalafil; Tumor Necrosis Factor-alpha	2017
Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiological reports, 2021, Volume: 9, Issue:16 Topics: Aged; Aged, 80 and over; Cyclic GMP; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Diastolic; Humans; Male; Myocardial Contraction; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Renal Elimination; Tadalafil	2021
Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure. Journal of the American Heart Association, 2022, 01-18, Volume: 11, Issue:2 Topics: Animals; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Glomerular Filtration Rate; Heart Failure; Humans; Natriuretic Peptide, Brain; Sodium; Tadalafil	2022

Other Studies

69 other study(ies) available for tadalafil and cyclic gmp

Article	Year
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Carbolines; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Hydantoins; Indicators and Reagents; Isomerism; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Tadalafil	2003
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues. Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Carbolines; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Hydantoins; Indicators and Reagents; Isomerism; Models, Molecular; Molecular Conformation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Tadalafil	2003
Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Molecular pharmacology, 2004, Volume: 66, Issue:1 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Binding Sites; Carbolines; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Imidazoles; Kinetics; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Protein Structure, Tertiary; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Tritium; Vardenafil Dihydrochloride	2004
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circulation research, 2005, Jan-07, Volume: 96, Issue:1 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adenoviridae; Adrenergic beta-Agonists; Animals; Carbolines; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fluorescence Resonance Energy Transfer; Genetic Vectors; Guanylate Cyclase; Isoproterenol; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Second Messenger Systems; Sildenafil Citrate; Soluble Guanylyl Cyclase; Sulfones; Tadalafil	2005
Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide. European journal of pharmacology, 2006, Jan-13, Volume: 530, Issue:1-2 Topics: Animals; Carbachol; Carbolines; Colforsin; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Drug Synergism; Electric Stimulation; Enzyme Activation; Enzyme Inhibitors; Guanylate Cyclase; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroglycerin; Oxadiazoles; Pyrazoles; Pyridines; Quinoxalines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Tadalafil; Tetrodotoxin	2006
Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. The journal of sexual medicine, 2006, Volume: 3, Issue:1 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Analysis of Variance; Carbolines; Cells, Cultured; Cyclic GMP; Humans; Male; Penile Erection; Penis; Phosphodiesterase Inhibitors; Tadalafil	2006
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain research, 2006, Nov-06, Volume: 1118, Issue:1 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Brain; Carbolines; Cell Proliferation; Cerebral Arteries; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Intracranial Embolism; Isoenzymes; Male; Microcirculation; Neovascularization, Physiologic; Neurons; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Recovery of Function; Stem Cells; Stroke; Tadalafil; Treatment Outcome	2006
Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Frontiers in bioscience : a journal and virtual library, 2007, Jan-01, Volume: 12 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Electrophoresis, Polyacrylamide Gel; Humans; Imidazoles; Ligands; Phosphodiesterase Inhibitors; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Protein Conformation; Protein Phosphatase 1; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Trypsin; Vardenafil Dihydrochloride	2007
Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum. British journal of pharmacology, 2007, Volume: 150, Issue:3 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Imidazoles; In Vitro Techniques; Male; Muscle, Smooth; Nitrergic Neurons; Nitric Oxide; Penis; Phosphodiesterase Inhibitors; Piperazines; Priapism; Purines; Rabbits; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride	2007
Oral phosphodiesterase-5 inhibitors: effect of heme oxygenase inhibition on cGMP signalling in rat cavernous tissue. Andrologia, 2007, Volume: 39, Issue:2 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Heme Oxygenase (Decyclizing); Imidazoles; Male; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride	2007
[PDE5 inhibitors. A new option in the treatment of ureteral colic?]. Der Urologe. Ausg. A, 2007, Volume: 46, Issue:9 Topics: Aged; Carbolines; Colic; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Isometric Contraction; Male; Middle Aged; Muscle, Smooth; Organ Culture Techniques; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Radioimmunoassay; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Ureter; Ureteral Calculi; Ureteral Diseases; Vardenafil Dihydrochloride	2007
Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:2 Topics: Animals; Carbolines; Catalytic Domain; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Sulfones; Tadalafil; Triazines; Tritium; Vardenafil Dihydrochloride	2007
Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry, 2007, Nov-27, Volume: 46, Issue:47 Topics: 1-Methyl-3-isobutylxanthine; Amino Acid Sequence; Animals; Binding Sites; Carbolines; Catalytic Domain; Crystallography, X-Ray; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Histidine; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Kinetics; Molecular Sequence Data; Mutation; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sequence Alignment; Sildenafil Citrate; Sulfones; Tadalafil; Thermodynamics; Triazines; Tyrosine; Vardenafil Dihydrochloride	2007
Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 325, Issue:1 Topics: Animals; Carbolines; Catalytic Domain; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Synergism; Humans; Hydrolysis; Phosphodiesterase 5 Inhibitors; Phosphorylation; Protein Binding; Tadalafil	2008
The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues. The journal of sexual medicine, 2008, Volume: 5, Issue:7 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic GMP; Heme Oxygenase (Decyclizing); Imidazoles; Male; Penis; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents	2008
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. Pharmacology, biochemistry, and behavior, 2009, Volume: 91, Issue:4 Topics: Animals; Antimetabolites; Apoptosis; Avoidance Learning; Brain Ischemia; Bromodeoxyuridine; Carbolines; Caspase 3; Cyclic GMP; Dentate Gyrus; Gerbillinae; Hippocampus; Immunohistochemistry; In Situ Nick-End Labeling; Memory, Short-Term; Neurons; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil	2009
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model. The Journal of thoracic and cardiovascular surgery, 2009, Volume: 137, Issue:5 Topics: Administration, Oral; Analysis of Variance; Animals; Carbolines; Cyclic GMP; Delayed-Action Preparations; Disease Models, Animal; Graft Rejection; Graft Survival; Immunohistochemistry; Lung Transplantation; Phosphodiesterase Inhibitors; Preoperative Care; Probability; Rabbits; Random Allocation; Reactive Oxygen Species; Reference Values; Reperfusion Injury; Tadalafil; Tissue and Organ Harvesting	2009
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. Cellular signalling, 2009, Volume: 21, Issue:12 Topics: Allosteric Regulation; Allosteric Site; Carbolines; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Electrophoresis, Gel, Two-Dimensional; Humans; Ligands; Magnesium; Phosphodiesterase 5 Inhibitors; Piperazines; Point Mutation; Purines; Sildenafil Citrate; Sulfones; Tadalafil	2009
Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action. The journal of sexual medicine, 2009, Volume: 6, Issue:10 Topics: Analysis of Variance; Animals; Area Under Curve; Arousal; Brain; Carbolines; Cyclic GMP; Dopamine; Female; Imidazoles; Male; Microdialysis; Muscle, Smooth; Nitric Oxide; Nucleus Accumbens; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Ventral Tegmental Area	2009
A new approach to the treatment of cerebral vasospasm: the angiographic effects of tadalafil on experimental vasospasm. Acta neurochirurgica, 2010, Volume: 152, Issue:3 Topics: Animals; Basilar Artery; Carbolines; Cerebral Angiography; Cerebral Arteries; Cerebrovascular Circulation; Cyclic GMP; Disease Models, Animal; Drug Administration Schedule; Male; Nitric Oxide; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Subarachnoid Hemorrhage; Tadalafil; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents; Vasospasm, Intracranial	2010
Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. Journal of pharmacological sciences, 2009, Volume: 111, Issue:3 Topics: Animals; Blood Gas Analysis; Carbolines; Cyclic GMP; Disease Progression; Dose-Response Relationship, Drug; Hemodynamics; Hydrogen-Ion Concentration; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Organ Size; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Poisons; Pulmonary Circulation; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Survival; Tadalafil	2009
cGMP is required for seed germination in Arabidopsis thaliana. Journal of plant physiology, 2010, Jul-15, Volume: 167, Issue:11 Topics: Abscisic Acid; Aminoquinolines; Arabidopsis; Carbolines; Cyclic GMP; Enzyme Inhibitors; Germination; Gibberellins; Guanylate Cyclase; Phosphodiesterase Inhibitors; Seeds; Tadalafil; Triazoles	2010
Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. Angiology, 2010, Volume: 61, Issue:6 Topics: Analysis of Variance; Blood Platelets; Carbolines; Cyclic AMP; Cyclic GMP; Dyslipidemias; E-Selectin; Endothelium, Vascular; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; P-Selectin; Phosphodiesterase Inhibitors; Pilot Projects; Risk Factors; Smoking; Tadalafil	2010
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. The Journal of pharmacology and experimental therapeutics, 2010, Sep-01, Volume: 334, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carbolines; Cardiomyopathies; Cell Line, Tumor; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Doxorubicin; GATA4 Transcription Factor; Genes, bcl-2; Hemodynamics; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myocytes, Cardiac; Neoplasm Transplantation; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Superoxide Dismutase; Tadalafil; Ultrasonography; Ventricular Function, Left	2010
Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology, 2010, Volume: 151, Issue:8 Topics: Carbolines; Cell Proliferation; Cell Transdifferentiation; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Down-Regulation; Drug Evaluation, Preclinical; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Humans; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostate; Prostatic Hyperplasia; RNA, Small Interfering; Stromal Cells; Tadalafil; Treatment Outcome	2010
Phosphodiesterase inhibition with tadalafil provides longer and sustained protection of stem cells. American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:5 Topics: Animals; Carbolines; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Graft Survival; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Models, Animal; Myocardial Infarction; Neovascularization, Physiologic; Phosphodiesterase Inhibitors; Rats; Rats, Inbred F344; Tadalafil; Time Factors	2010
Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors. Archiv der Pharmazie, 2011, Volume: 344, Issue:3 Topics: Carbolines; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Humans; Inhibitory Concentration 50; Phosphodiesterase 5 Inhibitors; Structure-Activity Relationship; Tadalafil	2011
Role of a novel tetrodotoxin-resistant sodium channel in the nitrergic relaxation of corpus cavernosum from the South American rattlesnake Crotalus durissus terrificus. The journal of sexual medicine, 2011, Volume: 8, Issue:6 Topics: Acetylcholine; Animals; Callithrix; Carbolines; Crotalus; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Endothelium, Vascular; In Vitro Techniques; Male; Microscopy, Electron, Scanning; NG-Nitroarginine Methyl Ester; Nitrergic Neurons; Nitric Oxide Synthase; Nitroprusside; Oxadiazoles; Penis; Pyrazoles; Pyridines; Quinoxalines; Sodium Channel Blockers; Sodium Channels; Tadalafil; Tetrodotoxin; Vasodilator Agents	2011
Drug to genome to drug: discovery of new antiplasmodial compounds. Journal of medicinal chemistry, 2011, May-12, Volume: 54, Issue:9 Topics: Amino Acid Sequence; Antimalarials; Carbolines; Catalytic Domain; Cyclic AMP; Cyclic GMP; Diketopiperazines; Drug Design; Drug Discovery; Genome, Human; Genome, Protozoan; Humans; Hydrolysis; Models, Molecular; Molecular Sequence Data; Parasitic Sensitivity Tests; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Plasmodium falciparum; Stereoisomerism; Structure-Activity Relationship; Tadalafil	2011
Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release. British journal of pharmacology, 2011, Volume: 164, Issue:2b Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthralgia; Arthritis, Experimental; Carbolines; Chemokine CXCL1; Chemokines; Cyclic GMP; Guanylate Cyclase; Injections, Intra-Articular; Interleukin-1; Joints; Male; Naloxone; Narcotic Antagonists; Neutrophils; Nociception; Osteoarthritis; Oxadiazoles; Quinoxalines; Rats; Rats, Wistar; Tadalafil; Tumor Necrosis Factor-alpha; Zymosan	2011
Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. Cellular signalling, 2011, Volume: 23, Issue:10 Topics: Allosteric Regulation; Allosteric Site; Animals; Carbolines; Carrier Proteins; Catalytic Domain; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Phosphodiesterase 5 Inhibitors; Phosphorylation; Piperazines; Protein Binding; Protein Conformation; Purines; Sildenafil Citrate; Substrate Specificity; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride	2011
Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction. Journal of Zhejiang University. Science. B, 2011, Volume: 12, Issue:6 Topics: Animals; Carbolines; Cyclic GMP; Erectile Dysfunction; Kidney Failure, Chronic; Male; Nitroprusside; Phosphodiesterase 5 Inhibitors; Rabbits; Tadalafil; Vasodilator Agents	2011
Effect of testosterone and frequent low-dose sildenafil/tadalafil on cavernous tissue oxidative stress of aged diabetic rats. Andrologia, 2012, Volume: 44, Issue:6 Topics: Aging; Animals; Carbolines; Cyclic GMP; Diabetes Mellitus, Experimental; Erectile Dysfunction; Glutathione Peroxidase; Male; Malondialdehyde; Oxidative Stress; Penile Erection; Penis; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone; Vasodilator Agents	2012
Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6. The Journal of biological chemistry, 2012, Nov-30, Volume: 287, Issue:49 Topics: Amino Acid Sequence; Amino Acids; Carbolines; Catalytic Domain; Cloning, Molecular; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 6; Drug Design; Enzyme Inhibitors; Evolution, Molecular; Eye Proteins; Humans; Imidazoles; Kinetics; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Binding; Retina; Sequence Homology, Amino Acid; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride	2012
Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. British journal of pharmacology, 2013, Volume: 169, Issue:2 Topics: Adult; Aged; Animals; Benzimidazoles; Carbolines; Cyclic GMP; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Erectile Dysfunction; Humans; Male; Middle Aged; Nitric Oxide; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Potassium Channels, Calcium-Activated; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilation; Vasodilator Agents	2013
Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. Journal of cardiology, 2013, Volume: 62, Issue:2 Topics: Animals; Antibiotics, Antineoplastic; Atrophy; Carbolines; Cardiomyopathies; Cardiotonic Agents; Cyclic GMP; Disease Models, Animal; Doxorubicin; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Ventricular Dysfunction, Left	2013
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Molecular cancer therapeutics, 2013, Volume: 12, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Carbolines; Cell Line; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclin D1; HCT116 Cells; HT29 Cells; Humans; Inhibitor of Apoptosis Proteins; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Sulindac; Survivin; Tadalafil; Wnt Signaling Pathway	2013
Effects of tadalafil on hemorrhagic cystitis and testicular dysfunction induced by cyclophosphamide in rats. Urologia internationalis, 2014, Volume: 93, Issue:1 Topics: Animals; Antioxidants; Body Weight; Carbolines; Cyclic GMP; Cyclophosphamide; Cystitis; Follicle Stimulating Hormone; Immunohistochemistry; Interleukin-10; Interleukin-6; Luteinizing Hormone; Male; Nitric Oxide; Organ Size; Rats; Rats, Sprague-Dawley; Sperm Count; Tadalafil; Temperature; Testis; Testosterone; Urological Agents	2014
Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia. Journal of pediatric surgery, 2014, Volume: 49, Issue:1 Topics: Animals; Carbolines; Cyclic GMP; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Induction; Female; Fetal Diseases; Fetal Therapies; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Maternal-Fetal Exchange; Nitric Oxide Synthase Type III; Organ Size; Phosphodiesterase 5 Inhibitors; Pregnancy; Random Allocation; Second Messenger Systems; Sheep; Tadalafil	2014
Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. The journal of sexual medicine, 2014, Volume: 11, Issue:5 Topics: Arteries; Benzopyrans; Carbolines; Cyclic GMP; Diabetes Mellitus, Type 2; Drug Synergism; Erectile Dysfunction; Ethanolamines; Humans; Imidazoles; Male; Middle Aged; Muscle Relaxation; Muscle, Smooth, Vascular; Nebivolol; Nitric Oxide; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents	2014
Molecular signalling of a novel curcumin derivative versus Tadalafil in erectile dysfunction. Andrologia, 2015, Volume: 47, Issue:6 Topics: Animals; Curcumin; Cyclic GMP; Diabetes Mellitus, Experimental; Erectile Dysfunction; Heme Oxygenase-1; Male; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase; p38 Mitogen-Activated Protein Kinases; Penis; Phosphodiesterase 5 Inhibitors; Rats; Tadalafil	2015
Effect of avanafil on rat and human corpus cavernosum. Andrologia, 2015, Volume: 47, Issue:8 Topics: Animals; Blood Pressure; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Male; Penis; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Tadalafil; Vasodilation	2015
Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling. Cell death & disease, 2014, Nov-27, Volume: 5 Topics: Animals; beta Catenin; Bone and Bones; Carbolines; Cell Differentiation; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Femur; Glycoproteins; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Organ Size; Osteoblasts; Phosphodiesterase 5 Inhibitors; Protein Stability; Tadalafil; Wnt Signaling Pathway	2014
Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors. European journal of pharmacology, 2014, Dec-15, Volume: 745 Topics: ATP-Binding Cassette Transporters; Caffeine; Carbolines; Cyclic AMP; Cyclic GMP; Dipyridamole; Humans; Imidazoles; Kinetics; Multidrug Resistance-Associated Proteins; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purinones; Sulfones; Tadalafil; Theophylline; Triazines; Vardenafil Dihydrochloride	2014
Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice. European journal of pharmacology, 2014, Dec-15, Volume: 745 Topics: Aging; Animals; Antioxidants; Carbolines; Cyclic GMP; Hippocampus; Male; Maze Learning; Memory, Short-Term; Mice; Motor Activity; Nitric Oxide; Nootropic Agents; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Tadalafil	2014
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PloS one, 2015, Volume: 10, Issue:6 Topics: Animals; Benzamides; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Hypertension, Pulmonary; Lung; Lung Compliance; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pyridines; Smoke; Smoking; Tadalafil	2015
Involvement of NO-cGMP pathway in anti-hyperalgesic effect of PDE5 inhibitor tadalafil in experimental hyperalgesia. Inflammopharmacology, 2015, Volume: 23, Issue:4 Topics: Animals; Carrageenan; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Tadalafil	2015
The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer letters, 2016, Jan-28, Volume: 370, Issue:2 Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Female; Guanylate Cyclase; Head and Neck Neoplasms; Humans; Mice; Phosphodiesterase 5 Inhibitors; Pyrazoles; Pyridines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Tadalafil	2016
Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine. Journal of the American Heart Association, 2016, Apr-20, Volume: 5, Issue:4 Topics: Adamantane; Animals; Atrial Natriuretic Factor; Cyclic GMP; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Echocardiography; Hypertrophy, Left Ventricular; Male; Natriuretic Peptide, Brain; Neuropeptide Y; Phosphodiesterase 5 Inhibitors; Signal Transduction; Swine; Swine, Miniature; Tadalafil; Ventricular Function, Left	2016
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation. The Journal of biological chemistry, 2016, 08-12, Volume: 291, Issue:33 Topics: Animals; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Disulfides; Doxorubicin; Heart Failure; Mice; Mice, Mutant Strains; Oxidation-Reduction; Phosphodiesterase 5 Inhibitors; rho-Associated Kinases; Second Messenger Systems; Tadalafil	2016
Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. Biochemical pharmacology, 2017, 12-01, Volume: 145 Topics: Blood Platelets; Chromatography, Liquid; Cyclic GMP; Humans; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Tandem Mass Spectrometry	2017
Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice. American journal of hypertension, 2017, Dec-08, Volume: 31, Issue:1 Topics: Animals; Blood Pressure; Cyclic GMP; Enzyme Inhibitors; Female; Fetal Development; Fetal Growth Retardation; Kidney; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Placenta; Pre-Eclampsia; Pregnancy; Proteinuria; Tadalafil	2017
The Nitric Oxide Pathway-A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension. The American journal of cardiology, 2017, 10-15, Volume: 120, Issue:8S Topics: Cyclic GMP; Drug Therapy, Combination; Endothelins; Enzyme Activators; Humans; Hypertension, Pulmonary; Molecular Targeted Therapy; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Precision Medicine; Pyrazoles; Pyrimidines; Signal Transduction; Sildenafil Citrate; Tadalafil	2017
Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5. Journal of pharmaceutical and biomedical analysis, 2018, Feb-05, Volume: 149 Topics: Catalytic Domain; Chemistry, Pharmaceutical; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Humans; Isoenzymes; Ligands; Models, Chemical; Molecular Docking Simulation; Phosphodiesterase 5 Inhibitors; Protein Binding; Recombinant Proteins; Rhodamines; Tadalafil	2018
Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase. Cardiovascular research, 2018, 05-01, Volume: 114, Issue:6 Topics: Animals; Benzoates; Cyclic GMP; Disease Models, Animal; Enzyme Activators; Female; Ischemic Postconditioning; Large-Conductance Calcium-Activated Potassium Channels; Male; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Tetrazoles; Thiourea; Time Factors; Up-Regulation	2018
Antinociceptive effect of tadalafil in various pain models: Involvement of opioid receptors and nitric oxide cyclic GMP pathway. Toxicology and applied pharmacology, 2018, 08-01, Volume: 352 Topics: Analgesics; Animals; Behavior, Animal; Cyclic GMP; Disease Models, Animal; Male; Mice, Inbred BALB C; Nitric Oxide; Nociceptive Pain; Pain Threshold; Receptors, Opioid; Second Messenger Systems; Tadalafil	2018
Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. American journal of physiology. Endocrinology and metabolism, 2018, 10-01, Volume: 315, Issue:4 Topics: Animals; Animals, Newborn; Bone and Bones; Bone Development; Cancellous Bone; Chondrocytes; Cortical Bone; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Epiphyses; Male; Natriuretic Peptide, C-Type; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tadalafil; Weight Gain; X-Ray Microtomography	2018
Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration. Neurobiology of disease, 2019, Volume: 121 Topics: Animals; Apoptosis; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Female; Glaucoma; Guanylate Cyclase; Mice, Knockout; Phosphodiesterase 5 Inhibitors; Rats, Sprague-Dawley; Retinal Degeneration; Retinal Ganglion Cells; Signal Transduction; Tadalafil	2019
Q817G mutation in phosphodiesterase type 5: Conformational analysis and dissociation profile of the inhibitor Tadalafil. Chemical biology & drug design, 2019, Volume: 93, Issue:4 Topics: Binding Sites; Catalytic Domain; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Hydrogen Bonding; Ligands; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Phosphodiesterase 5 Inhibitors; Tadalafil; Thermodynamics	2019
Intranasal Tadalafil nanoemulsions: formulation, characterization and pharmacodynamic evaluation. Pharmaceutical development and technology, 2019, Volume: 24, Issue:9 Topics: Administration, Intranasal; Animals; Cyclic GMP; Emulsions; Male; Phase Transition; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Solubility; Tadalafil; Vasodilator Agents	2019
Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome. Life sciences, 2020, Sep-01, Volume: 256 Topics: Animals; Colon; Constipation; Cyclic GMP; Feces; Gastrointestinal Transit; Hippocampus; Intestine, Large; Irritable Bowel Syndrome; Male; Peptides; Proto-Oncogene Proteins c-fos; Rats, Wistar; Reflex; Swimming; Tadalafil; Water	2020
Preserved activity of soluble guanylate cyclase (sGC) in iliac artery from middle-aged rats: Role of sGC modulators. Nitric oxide : biology and chemistry, 2021, 01-01, Volume: 106 Topics: Acetylcholine; Aging; Animals; Benzoates; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Iliac Artery; Male; Nitric Oxide; Nitroprusside; Pyrazoles; Pyridines; Rats, Wistar; Reactive Oxygen Species; Soluble Guanylyl Cyclase; Tadalafil; Vasodilation; Vasodilator Agents	2021
Possible protective effect of TNF-α inhibition and triad NO/cGMP/VEGF activation on gastric ulcer in rats. Canadian journal of physiology and pharmacology, 2021, Volume: 99, Issue:9 Topics: Animals; Cyclic GMP; Dinoprostone; Indomethacin; Male; Malondialdehyde; Nitric Oxide; Pentoxifylline; Rats; Stomach Ulcer; Tadalafil; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2021
Tadalafil Reversed H-89 - and Scopolamine - Induced Spatial Learning Impairments in Male Rats. Drug research, 2021, Volume: 71, Issue:5 Topics: Animals; Cyclic AMP Response Element-Binding Protein; Cyclic GMP; Hippocampus; Isoquinolines; Male; Maze Learning; Memory; Rats; Rats, Wistar; Scopolamine; Signal Transduction; Spatial Learning; Sulfonamides; Tadalafil	2021
Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway. Pharmacological reports : PR, 2021, Volume: 73, Issue:5 Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic GMP; Cyclopropanes; Cytokines; Gene Expression Regulation; Hippocampus; Male; Memory Disorders; Morris Water Maze Test; Oxidative Stress; Peptide Fragments; Random Allocation; Rats; Rats, Wistar; Tadalafil; Vasodilator Agents	2021
[Role of NO-cGMP-PKG axis in pulmonary arterial hypertension]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2022, Volume: 157, Issue:4 Topics: Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Tadalafil	2022
Improvement of cognitive dysfunction by a novel phosphodiesterase type 5 inhibitor, Tadalafil. Fundamental & clinical pharmacology, 2023, Volume: 37, Issue:2 Topics: Cognitive Dysfunction; Cyclic GMP; Humans; Memory Disorders; NG-Nitroarginine Methyl Ester; Phosphodiesterase 5 Inhibitors; Scopolamine; Tadalafil	2023
Inhibition of multidrug resistance proteins by MK571 restored the erectile function in obese mice through cGMP accumulation. Andrology, 2023, Volume: 11, Issue:3 Topics: Acetylcholine; Animals; ATP Binding Cassette Transporter, Subfamily B; Cyclic GMP; Erectile Dysfunction; Humans; Male; Mice; Mice, Obese; Nitroprusside; Obesity; Tadalafil	2023
Inhibition of phosphodiesterase 5A by tadalafil improves SIRT1 expression and activity in insulin-resistant podocytes. Cellular signalling, 2023, Volume: 105 Topics: AMP-Activated Protein Kinases; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetic Nephropathies; Glucose; Humans; Hyperglycemia; Insulin; Insulin Resistance; Podocytes; Sirtuin 1; Tadalafil	2023